IDIA Stock Analysis: Idorsia | SW
Biotechnology | SW, Switzerland | Market Cap: 1.631m CHF | 12M Return: 186% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.2M
Qual. Beats: 0
Rev. Trend: 51.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Idorsia Ltd is a Swiss biopharmaceutical company that discovers, develops, and commercializes drugs targeting unmet medical needs across Switzerland, the United States, Japan, Europe, China, and Canada. Its lead commercial product is QUVIVIQ (daridorexant), a treatment for insomnia, and the company maintains a clinical pipeline spanning CNS, cardiovascular, immunological, and orphan disease indications, including late-stage candidates such as Lucerastat in Phase 3 for Fabry disease and earlier-stage programs in areas like psoriasis, vitiligo, and multiple sclerosis. The business model is typical of small-cap biotechs, relying on long, capital-intensive R&D cycles, a mix of in-house development and licensing revenues, and strategic collaborations with larger pharmaceutical partners-Idorsia has partnership agreements with Neuro, Janssen Biotech, and Viatris to co-develop and commercialize assets such as clazosentan, aprocitentan, selatogrel, and cenerimod. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
- QUVIVIQ daridorexant launch drives insomnia revenue growth
- Lucerastat Phase 3 Fabry disease readout approaches
- Cash burn and potential capital raise pressure shares
| Net Income: -220.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA 42.97 > 1.0 |
| NWC/Revenue: 41.01% < 20% (prev -87.42%; Δ 128.4% < -1%) |
| CFO/TA -0.26 > 3% & CFO -125.9m > Net Income -220.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.7m) vs 12m ago 38.48% < -2% |
| Gross Margin: 86.00% > 18% (prev 30.68%; Δ 55.32% > 0.5%) |
| Asset Turnover: 46.79% > 50% (prev 35.37%; Δ 11.42% > 0%) |
| Interest Coverage Ratio: -2.95 > 6 (EBIT TTM -160.5m / Interest Expense TTM 54.4m) |
| A: 0.19 (Total Current Assets 239.6m - Total Current Liabilities 149.7m) / Total Assets 480.5m |
| B: -7.42 (Retained Earnings -3.56b / Total Assets 480.5m) |
| C: -0.34 (EBIT TTM -160.5m / Avg Total Assets 468.3m) |
| D: -0.71 (Book Value of Equity -1.18b / Total Liabilities 1.66b) |
| Altman-Z'' = -26.01 = D |
| DSRI: 1.20 (Receivables 55.3m/33.9m, Revenue 219.1m/161.3m) |
| GMI: 0.36 (GM 30.68% / 86.00%) |
| AQI: 0.87 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.36 (Revenue 219.1m / 161.3m) |
| TATA: -0.20 (NI -220.8m - CFO -125.9m) / TA 480.5m) |
| Beneish M = -3.29 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at CHF 6.55 with a total of 1,413,986 shares traded. Over the past week, the price has changed by -4.59%, over one month by +55.21%, over three months by +92.31% and over the past year by +186.03%.
Current recommended Stop Loss: 6.00 (which is 8.4% or 1.3 ATR below the current price).
Idorsia has no consensus analysts rating.
P/S = 7.5082
P/B = 27.6461
Revenue TTM = 219.1m CHF
EBIT TTM = -160.5m CHF
EBITDA TTM = -143.6m CHF
Long Term Debt = 1.21b CHF (from longTermDebt, last quarter)
Short Term Debt = 22.7m CHF (from shortTermDebt, last quarter)
Debt = 1.43b CHF (from shortLongTermDebtTotal, last quarter) + Leases 109.5m
Net Debt = 1.33b CHF (calculated: Debt 1.43b - CCE 94.7m)
Enterprise Value = 2.97b CHF (1.63b + Debt 1.43b - CCE 94.7m)
Interest Coverage Ratio = -2.95 (Ebit TTM -160.5m / Interest Expense TTM 54.4m)
EV/FCF = -21.13x (Enterprise Value 2.97b / FCF TTM -140.3m)
FCF Yield = -4.73% (FCF TTM -140.3m / Enterprise Value 2.97b)
FCF Margin = -64.04% (FCF TTM -140.3m / Revenue TTM 219.1m)
Net Margin = -100.7% (Net Income TTM -220.8m / Revenue TTM 219.1m)
Gross Margin = 86.00% ((Revenue TTM 219.1m - Cost of Revenue TTM 30.7m) / Revenue TTM)
Gross Margin QoQ = 85.95% (prev 80.44%)
Tobins Q-Ratio = 6.17 (Enterprise Value 2.97b / Total Assets 480.5m)
Interest Expense / Debt = 3.81% (Interest Expense 54.4m / Debt 1.43b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -120.4m (EBIT -160.5m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.60 (Total Current Assets 239.6m / Total Current Liabilities 149.7m)
Debt / Equity = -1.21 (negative equity) (Debt 1.43b / totalStockholderEquity, last quarter -1.18b)
Debt / EBITDA = -9.29 (negative EBITDA) (Net Debt 1.33b / EBITDA -143.6m)
Debt / FCF = -9.51 (negative FCF - burning cash) (Net Debt 1.33b / FCF TTM -140.3m)
Total Stockholder Equity = -1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -47.14% (Net Income -220.8m / Total Assets 480.5m)
RoE = 19.23% (negative equity) (Net Income TTM -220.8m / Total Stockholder Equity -1.15b)
RoCE = -257.5% (out of range, set to none) (EBIT -160.5m / Capital Employed (Equity -1.15b + L.T.Debt 1.21b))
RoIC = -35.15% (negative operating profit) (NOPAT -120.4m / Invested Capital 342.5m)
WACC = 5.78% (E(1.63b)/V(3.06b) * Re(8.34%) + D(1.43b)/V(3.06b) * Rd(3.81%) * (1-Tc(0.25)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 16.67%
[DCF] Fair Price = unknown (Cash Flow -140.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.10 | # QB: 0
Revenue Correlation: 51.18 | Revenue CAGR: 21.48% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.23 | Chg30d=-21.05% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.22 | Chg30d=-22.22% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.13 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+7.9% | GrowthRev=-0.2%
EPS next Year (2027-12-31): EPS=0.06 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+142.8% | GrowthRev=+23.7%